Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial
Latest Information Update: 06 Feb 2024
At a glance
- Drugs BAY 1097761 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Therapeutic Use
- Acronyms SEAL
- Sponsors Bayer
Most Recent Events
- 13 Apr 2023 Status changed from active, no longer recruiting to discontinued.
- 30 Mar 2023 This trial has been discontinued in Denmark, Hungary and Slovakia according to European Clinical Trials Database record
- 30 Mar 2023 The trial has been completed in Czech Republic, according to European Clinical Trials Database record.